星空游戏网站免费进入|星空彩票电脑版

Abstract

CLC Number:

R964

WU Zhi-gang，SHEN Li-xia.Treatment for Lower Urinary Tract Dysfunction in Patients with Parkinson’s Disease[J]. Acta Neuropharmacologica, 2014, 4(4): 36-41.

[1] Jain S. Multi-organ autonomic dysfunction in Parkinson disease. Parkinsonism Relat Disord. 2011, 17(2):77-83.

[2] Badri AV, Purohit RS, Skenazy J, et al. A review of lower urinary tract symptoms in patients with Parkinson's disease. Curr Urol Rep. 2014, 15(9):435-443.

[3] Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008, 9(6):453-466.

[4] 胡钢. 帕金森病膀胱尿道功能障碍的研究[D]. 重庆,重庆医科大学,2007:21-22.

[5] 姜良真. 耻骨上经膀胱前列腺切除术与耻骨后前列腺切除术手术疗效比较及神经原性膀胱的尿动力学分析[D]. 天津,天津医科大学,2009:50-51.

[6] Aranda B, Cramer P. Effect of apomorphine and L-dopa on the parkinsonian bladder. Neurourol Urodyn. 1993, 12(3): 203-209.

[7] Winge K, Werdelin LM, Nielsen KK, et al. Effects of dopaminergic treatment on bladder function in Parkinson's disease. Neurourol Urodyn. 2004, 23(7):689-696.

[8] Kuno S, Mizuta E, Yamasaki S, et al. Effects of pergolide on nocturia in Parkinson’s disease: three female cases selected from over 400 patients. Parkinsonism Relat Disord. 2004, 10(3):181-187.

[9] Fitzmaurice H, Fowler CJ, Rickards D, et al. Micturition disturbance in Parkinson’s disease. Br J Urol. 1985; 57(6):652-656.

[10] Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson’s disease. Trend Neurosci. 2000; 23(10 Suppl): S2–S7.

[11] 孙颖浩. ?1受体阻滞剂治疗良性前列腺增生研究进展[J]. 中华男科学杂志,2004,10(7):483-485.

[12] Gomes CM, Sammour ZM, Bessa Junior Jd, et al. Neurological status predicts response to alpha-blockers in men with voiding dysfunction and Parkinson's disease. Clinics (Sao Paulo). 2014, 69(12):817-822.

[13] Donnellan CA, Fook L, McDonald P, et al. Oxybutynin and cognitive dysfunction. BMJ 1997, 315(7119):1363–1364.

[14] 张辰珠,姚建. 曲司氯铵治疗膀胱过动症[J]. 世界临床药物, 2006, 27(6):359-363.

[15] 薛晓岩,于天民. 达非那新治疗特发性急迫性尿失禁30例[J]. 中国民康医学,2013,25(11):73-74.

[16] Dykstra DD, Sidi AA, Scott AB, et al. Effects of botulinum toxin A on detrusor sphincter dyssynergia in spinal cord injury patients. J Urol. 1988,139(5):919–922

[17] 陈俊男. A型肉毒毒素对神经和肌肉影响的效价研究[D].上海市, 第二军医大学,2008:1-2.

[18] Kapoor S, Bourdoumis A, Mambu L, et al. Effective management of lower urinary tract dysfunction in idiopathic Parkinson’s Disease. Int J Urol. 2013; 20(1):79–84.

[19] Giannantoni A, Conte A, Proietti S, et al. Botulinum toxin type A in patients with Parkinson’s disease and refractory overactive bladder. J Urol. 2011, 186(3):960–964.

[20] Cone EB, Ellsworth P. Neurogenic detrusor overactivity: an update on management options. R I Med J. 2013, 96(4):38–40.

[21] Sakakibara R, Ito T, Uchiyama T, et al. Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment. Urol Int. 2008, 81(3):335–339.

[22] Suchowersky O, Furtado S, Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson’s disease. Mov Disord.1995, 10(3):337–340.

[23] Igawa Y, Michel MC. Pharmacological profile of β3-adrenoceptor agonists in clincal development for the treatment of overactive bladder syndrome. Naunyn Schmiedebergs Arch Pharmacol. 2013, 386(3):177–183.

[24] 何鹏彬,查培金,徐东萍. 磷酸二酯酶-5抑制剂治疗良性前列腺增生所致下尿路症状的研究进展[J].中华男科学杂志,2014,20(7):651-654.

[25] Proietti S, Giannantoni A, Sahai A, et al. Overactive bladder and sexual function: a nightmare couple. BJU Int. 2012, 110(7):921–924.

[26] Ashkan K, Samuel M, Reddy P, et al. The impact of deep brain stimulation on the nonmotor symptoms of Parkinson's disease. J Neural Transm. 2013, 120(4):639-642.

[27] Dostrovsky JO, Lozano AM. Mechanisms of deep brain stimulation. Mov Disord. 2002, 17 (Supple 3): S63–S68.

[28] Shimizu N1, Matsumoto S, Mori Y, et al. Effects of deep brain stimulation on urodynamic findings in patients with Parkinson's disease. Hinyokika Kiyo. 2007, 53(9):609-612.

[29] Phé V, Caremel R, Bart S, et al. Lower urinary tract dysfunctions in parkinsonian syndromes: a review by the Neuro-Urology Comittee of the French Association of Urology. Prog Urol.2013, 23(5):296–308.

[30] Ohannessian A, Kaboré FA, Agostini A, et al. Transcutaneous tibial nerve stimulation in the overactive bladder syndrome in patients with Parkinson’s syndromes. Prog Urol. 2013, 23(11):936–939.

[31] Staskin DS, Vardi Y, Siroky MB. Post-prostatectomy continence in the parkinsonian patient: the significance of poor voluntary sphincter control. J Urol. 1988, 140(1):117–118.

[32] Roth B, Studer UE, Fowler CJ, et al. Benign prostatic obstruction and parkinson’s disease-should transurethral resection of the prostate be avoided? J Urol. 2009, 181(5):2209–2213.

[33] Lehana Yeo, Rajindra Singh, Mohan Gundeti, et al. Urinary tract dysfunction in Parkinson’s disease: a review [J]. Int Urol Nephrol.2012, 44(2):415-424.

[34] 黄嘉,张庆霞,梁文蔚. 艾灸治疗帕金森病排尿障碍31例[J]. 中国中医药现代远程教育,2012,10(7):46-47.

[35] 陈义良,张小莉,周国林. 针灸推拿结合药物治疗脑外伤后综合征42例临床观察[J]. 江苏中医药,2010,42(4):53-54.

[36] 陈义良,冯为菊,张小莉. 针药结合治疗帕金森病合并膀胱过度活动症[J]. 中国针灸,2012,32(3):215-218.

Treatment for Lower Urinary Tract Dysfunction in Patients with Parkinson’s Disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

[1]	LI Hui, YANG Jin-shui, XUE Qian.A Case of Huntington's Disease with Involuntary Movements of the Limbs as the First Symptom Combined with Dysarthria in the Early Stages of the Disease[J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(6): 31-.
[2]	ZHANG Yuan-qing, LIN Yu, HUANG Li.Study on the Effects of Vitamin D on DNA Methylation in Alzheimer's Disease Cell Models[J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(6): 39-.
[3]	ZHAO Yu-ting, YIN Hong-yan, GUO Chun-yan.Explore the Mechanism of Paeoniae Radix Alba Delaying Alzheimer's Disease Based on Network Pharmacology and Molecular Docking[J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(5): 1-.
[4]	ZHANG Xin, YAO Si-fan, MA Meng-fan, SHEN Li-xia.Recent Progress in the Metabolomics of Alzheimer's Disease[J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(5): 47-.
[5]	HAO Xue-nan, YANG Lei, ZHAO Wen-ya, ZHANG Wei.Research Progress on the Etiology of Febrile Seizures and the Treatment[J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(4): 42-.
[6]	YAO Si-fan, ZHANG Xin, SHEN Li-xia.Effects of Tau Protein on Mitochondrial Function in Alzheimer's Disease[J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(4): 54-.
[7]	WANG Tian-xu, LIU Ci, CUI Yong-yuan, ZHANG Xin, WU Miao-miao, SHEN Li-xia.Explore the Mechanism of Quercetin in the Treatment of Alzheimer's Disease by Network Pharmacology and Molecular Docking[J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(2): 31-.
[8]	YIN Hong-yan, YOU Si-han, GUO Chun-yan.Research Progress of Core Markers and Other Markers of Alzheimer's Disease[J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(6): 45-.
[9]	ZHU Jing-yi , FAN Jian-chun, YU Ai-mei.Research Status on the Neuroprotective Effect of Probucol[J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(6): 50-.
[10]	.Exploring the Effect and Mechanism of Pterostilbene on Alzheimer’s Disease Based on Network Pharmacology[J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(5): 1-.
[11]	YOU Si-han, YIN Hong-yan, YANG Song-rui, LIU Xin-miao, GUO Chun-yan.Advance in Pretreatment Techniques for Biological Samples[J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(5): 52-.
[12]	BAI Jing-ru, YOU Si-han, YIN Hong-yan, YANG Song-rui, GUO Chun-yan.Predicting the Target of Peach Kernel in the Treatment of Parkinson's Disease Based on Network Pharmacology[J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(3): 31-.
[13]	GUO Bao, LIU Zi-ming, JING Yong-shuai, ZHANG Dan-shen.Correlation Between Wnt Signaling Pathway and Alzheimer's Disease and Its Targets[J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(1): 56-.
[14]	SI Wen-ying, HOU Yu-qing, SUN Xiao-jing, MENG Xian-yong, DONG Xiao-hua.Gene Therapy for Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2022, 12(6): 51-56.
[15]	ZHANG Zhi-qing, ZHANG Yong-cai, LIU Lin-xuan, LI Ren-qing, LIU Ji-jia, DU Jing-kao, JIANG Bei, WEI Huiping, SU Li-ning.Bioinformatics Analysis of the Relationship between Exosomal ceRNA Regulatory Network and Alzheimer’s Disease[J]. ACTA NEUROPHARMACOLOGICA, 2022, 12(4): 23-40.